

Binding Commitments Secured for Strategic A\$1.275 million Placement to Advance Commercialisation Strategy

Key Highlights

- **Binding commitments secured to raise A\$1.275 million from new and existing shareholders, demonstrating broadening market interest and continued strong support for Memphasys' commercialisation strategy**
- **Funds to be used to progress runway for registration, licensing, joint venture and distribution agreements for the Felix™ System following successful pivotal clinical trial results**
- **Felix™ System clinically validated as safe, faster, not inferior to Swim-up and superior to density Gradient Centrifugation**
- **RoXsta™ has shown strong potential for livestock reproductive and animal health applications, including early mastitis detection in dairy cattle**

Memphasys Limited (ASX: MEM) (Memphasys or the Company), an Australian reproductive biotechnology company, is pleased to announce that it has received binding commitments from new and existing shareholders to raise A\$1.275 million through a strategic Placement (Placement) of 212,500,000 ordinary shares at \$0.006 per share.

Participants in the Placement will also receive one (1) free attaching option for every share subscribed for. Each option will be exercisable at \$0.011 and will expire on 15 April 2027.

The Placement has been conducted using the Company's existing placement capacity under ASX Listing Rules 7.1 and 7.1A and therefore does not require shareholder approval.

Use of Funds

Proceeds from the Placement will be used to:

- Advance strategic discussions across the Felix™ and RoXsta™ platforms, including licensing, JV, and distribution opportunities
- Fund market access and regulatory submissions for Felix™ in key regions
- Support the ongoing RoXsta™ bull fertility and dairy mastitis studies
- Provide general working capital for operational execution

CEO and Managing Director, Dr David Ali, said:

"The strong participation from new and existing shareholders reflects growing market interest, continued belief in our strategy and the significant commercial opportunity in front of us. The recent Felix™ clinical trial outcome validates our technology and has already driven deeper engagement with partners globally. RoXsta™ is steadily gaining traction and is set for a solid future across multiple applications."

Commercialisation Pathway: Felix™ System

The Felix™ System is Memphasys' flagship device for use in human Assisted Reproductive Technology (ART), designed to gently and efficiently separate high-quality sperm using a proprietary electrophoresis-based method.

In late March 2025, the Company announced completion of its pivotal clinical trial, conducted in collaboration with Monash IVF. The trial met its primary endpoint, demonstrating that Felix™ achieved non-inferior embryo utilisation rates compared to Swim-Up and statistically superior outcomes to Density Gradient Centrifugation (DGC), the most used sperm preparation method globally.¹

Key trial outcomes included:

- No adverse events reported during use
- Faster sperm selection than both DGC and Swim-Up
- 100% of embryology staff preferred Felix™ over DGC, with over 50% preferring it over Swim-Up
- Validation for use in regulated markets, supporting upcoming CE Mark, TGA, and CDSCO submissions

These results have laid the foundation for deeper engagement with global commercial partners. Felix™ has distribution agreements in place with Vitrolife (Japan, Canada, New Zealand), a Letter of Intent with Heranova in China, and R&D sales in the UAE. These discussions are aimed at transitioning into potential joint ventures and scaled distribution initiatives.

Shareholders should note that these discussions are currently confidential and incomplete in nature and there is no guarantee that these will proceed to a binding agreement, which would require disclosure to the ASX.

RoXsta™ System: Veterinary Applications and Strategic Partnerships

Memphasys is also advancing its second platform, RoXsta™, an antioxidant assay system designed to assess oxidative stress

A recent heifer study, conducted at the request of industry stakeholders, confirmed that RoXsta™ provides accurate and reproducible antioxidant measurements in commercial agricultural settings.² While the study did not show a statistically significant correlation to pregnancy outcome in heifers, it highlighted the system's technical robustness and suggested more compelling applications in bulls and dairy cattle.

RoXsta™ also showed early promise in detecting mastitis, an inflammatory condition impacting ~17% of dairy cattle worldwide

Additional Information

Settlement of the Placement is expected to occur on Tuesday, 15 April 2025, with the issue of shares and options to follow shortly thereafter. An Appendix 3B has been lodged separately with the ASX.

Authorised by the Board of Memphasys Limited.

¹ Refer ASX announcement dated 24 March 2025: "Felix™ Clinical Trial Confirms Best-in-Class Performance"

² Refer ASX announcement dated 3 April 2025: "RoXsta™ Delivers Effective Oxidative Stress Measurement in Cattle"

Ends

For further information, please contact:

Dr. David Ali
Managing Director & CEO
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

David Tasker
Managing Director
Chapter One Advisors
Tel: +61 433 112 936
E: dtasker@chapteroneadvisors.com.au

About Memphasys Limited

Memphasys Limited (ASX: MEM) specialises in advanced reproductive biotechnology, developing medical devices, diagnostics, and proprietary media for human and animal applications. With flagship technologies like the Felix™ and RoXsta™ Systems, Memphasys is committed to delivering transformative solutions that enhance fertility outcomes worldwide.

Website: www.memphasys.com